Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      MAYPHARM CO., LTD. lanza SKINCOLLA, relleno de colágeno humano para rejuvenecimiento de la piel


      News provided by

      Maypharm

      Feb 14, 2025, 06:27 ET

      Share this article

      Share this article


      -MAYPHARM CO., LTD. lanza SKINCOLLA: El primer relleno de colágeno humano recombinante del mundo para un rejuvenecimiento superior de la piel

      Una tecnología innovadora que combina colágeno humano recombinante y ácido hialurónico para obtener resultados inmediatos y duraderos

      SEUL, Corea del Sur, 14 de febrero de 2025 /PRNewswire/ -- MAYPHARM CO., LTD. se enorgullece de presentar SKINCOLLA, el primer relleno de colágeno humano recombinante del mundo, que marca un avance significativo en la tecnología de rejuvenecimiento de la piel. Al utilizar colágeno recombinante Demulcent™ Tipo I, SKINCOLLA ofrece una solución natural para lograr una piel joven y revitalizada.

      Tecnología revolucionaria de relleno de colágeno

      Continue Reading
      MAYPHARM CO., LTD. Launches SKINCOLLA: The World’s First Recombinant Human Collagen Filler for Superior Skin Rejuvenation
      MAYPHARM CO., LTD. Launches SKINCOLLA: The World’s First Recombinant Human Collagen Filler for Superior Skin Rejuvenation

      SKINCOLLA es un producto innovador en el campo de los tratamientos estéticos. Combina colágeno recombinante 100 % idéntico al humano con ácido hialurónico (AH), lo que proporciona mejoras inmediatas y duraderas en la textura, elasticidad e hidratación de la piel. Esta fórmula de vanguardia imita el colágeno natural del cuerpo, restaurando la firmeza y la suavidad y abordando los signos comunes del envejecimiento, como las arrugas, la flacidez y la pérdida de volumen.

      ¿Por qué utilizar colágeno humano recombinante?

      Altamente respetuoso con el cuerpo: el colágeno recombinante de SKINCOLLA es genéticamente idéntico al colágeno humano, lo que garantiza una biocompatibilidad superior y minimiza el riesgo de reacciones alérgicas.

      Sin aditivos sintéticos, SKINCOLLA garantiza un rejuvenecimiento óptimo, lo que lo convierte en una opción confiable para mejorar la piel.

      Dolor mínimo y sin tiempo de inactividad: gracias a su similitud estructural con el colágeno natural, las inyecciones de SKINCOLLA son menos dolorosas y el tratamiento no requiere tiempo de inactividad, lo que permite a los pacientes volver a sus actividades diarias de inmediato.

      Sensibilidad cultural: SKINCOLLA está diseñado teniendo en cuenta las diversas preferencias culturales y religiosas, lo que garantiza que sea adecuado para pacientes de todos los orígenes, incluidos aquellos que se adhieren a las pautas islámicas.

      Tecnología de vanguardia para resultados duraderos

      El colágeno recombinante Demulcent™ Tipo I patentado de SKINCOLLA se produce en un entorno controlado y de alta tecnología. La inclusión de 50 mg de AH en la fórmula mejora aún más la hidratación, lo que proporciona una solución de doble acción que amplifica los efectos rejuvenecedores.

      ¿Quién puede beneficiarse de SKINCOLLA?

      SKINCOLLA es ideal para personas que buscan:

      Resultados naturales y sutiles sin el aspecto "exagerado" que suele asociarse con los rellenos tradicionales.

      Rejuvenecimiento cutáneo no invasivo para mejorar la elasticidad, la firmeza y la hidratación.

      Beneficios antienvejecimiento a largo plazo, que estimulan la producción de colágeno para una mejora sostenida de la piel.

      Indicaciones de SKINCOLLA

      Arrugas faciales: arrugas del cuello, surcos nasolabiales, líneas de la frente, patas de gallo y líneas de marioneta.

      Ojos: reducción de ojeras, arrugas de los ojos e hinchazón.

      Cuerpo: reafirmación y luminosidad de la piel en zonas como manos, rodillas, codos y axilas.

      Para obtener más información sobre SKINCOLLA y otros productos de MAYPHARM CO., LTD., visite www.maypharm.net o contacte [email protected].

      Foto - https://mma.prnewswire.com/media/2620398/MAYPHARM_CO_LTD_Launches_SKINCOLLA_The_World_s_First_Recombinant_Human.jpg

      Modal title

      Also from this source

      MAYPHARM stellt HYALMASS AQUATOX vor, eine multiaktive Hautpflege der nächsten Generation für den globalen Markt für ästhetische Medizin

      MAYPHARM stellt HYALMASS AQUATOX vor, eine multiaktive Hautpflege der nächsten Generation für den globalen Markt für ästhetische Medizin

      MAYPHARM, ein weltweit tätiges Unternehmen im Bereich Ästhetik und Kosmezeutika, hat die bevorstehende Markteinführung von HYALMASS AQUATOX...

      MAYPHARM dévoile HYALMASS AQUATOX, une solution multi-active de nouvelle génération pour la peau, destinée au marché mondial de l'esthétique

      MAYPHARM dévoile HYALMASS AQUATOX, une solution multi-active de nouvelle génération pour la peau, destinée au marché mondial de l'esthétique

      MAYPHARM, une entreprise internationale spécialisée dans l'esthétique et les cosméceutiques, a annoncé le lancement prochain de HYALMASS AQUATOX, une ...

      More Releases From This Source

      Explore

      Cosmetics and Personal Care

      Cosmetics and Personal Care

      Household, Consumer & Cosmetics

      Household, Consumer & Cosmetics

      Biotechnology

      Biotechnology

      Health Care & Hospitals

      Health Care & Hospitals

      News Releases in Similar Topics

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.